



Universiteit  
Leiden  
The Netherlands

## Exploiting HLA-alloreactivity in TCR gene therapy of B cell malignancies

Jahn, L.

### Citation

Jahn, L. (2017, April 19). *Exploiting HLA-alloreactivity in TCR gene therapy of B cell malignancies*. Retrieved from <https://hdl.handle.net/1887/48861>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/48861>

**Note:** To cite this publication please use the final published version (if applicable).

**Exploiting HLA-alloreactivity in TCR Gene Therapy  
of B Cell Malignancies**

Lorenz Jahn

Exploiting HLA-alloreactivity in TCR Gene Therapy of B Cell Malignancies  
© 2017 Lorenz Jahn, New York

Cover Image: Copyright © 2009 Martin Handford  
From WHERE'S WALLY? THE INCREDIBLE PAPER CHASE by  
Martin Handford  
Reproduced by kind permission of Walker Books Ltd,  
London SE11 5HJ

Printing: Ipskamp Drukkers, Enschede, The Netherlands

ISBN: 978-94-028-0555-0

The research described in this thesis was supported by the financial assistance of the Dutch Cancer Society (2010–4832) and the Landsteiner Foundation for Blood Transfusion Research (LSBR0713).

Printing of this thesis was financially supported by Fonds Stimulans and the Jim Reekers Foundation.

# **Exploiting HLA-alloreactivity in TCR Gene Therapy of B Cell Malignancies**

Proefschrift

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op woensdag 19 april 2017  
klokke 15.00 uur

door

Lorenz Jahn

geboren te Greifswald, DDR  
in 1985

Promotor:

**Prof. dr. J.H.F. Falkenburg**

Co-promotor:

**Dr. M.H.M. Heemskerk**

Leden promotiecommissie:

**Prof. dr. T.N.M. Schumacher**

**Prof. dr. M.J. Kersten**

*(Universiteit van Amsterdam)*

**Dr. T. Mutis**

*(Vrije Universiteit Amsterdam)*

# Contents

<b>Chapter 1</b>	General Introduction and Aim of the Study	<b>7</b>
<b>Chapter 2</b>	Generation of CD20-specific TCRs for TCR Gene Therapy of CD20 <sup>low</sup> B-cell Malignancies Insusceptible to CD20-targeting Antibodies	<b>35</b>
<b>Chapter 3</b>	A CD22-reactive TCR from the T-cell Allorepertoire for the Treatment of Acute Lymphoblastic Leukemia by TCR Gene Transfer	<b>71</b>
<b>Chapter 4</b>	Therapeutic Targeting of the BCR Associated Protein CD79b in a TCR-based Approach Is Hampered by Aberrant Expression of CD79b	<b>95</b>
<b>Chapter 5</b>	TCR-based Therapy for Multiple Myeloma and Other B-cell Malignancies Targeting Intracellular Transcription Factor BOB1	<b>119</b>
<b>Chapter 6</b>	Summary and General Discussion	<b>147</b>
<b>Appendices</b>	Nederlandse Samenvatting	<b>169</b>
	Dankwoord	<b>177</b>
	Curriculum Vitae	<b>178</b>
	List of Publications	<b>179</b>

